Creative Planning’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.98M | Buy |
24,122
+307
| +1% | +$104K | 0.01% | 843 |
|
|
2025
Q4 | $9.47M | Buy |
23,815
+953
| +4% | +$422K | 0.01% | 642 |
|
|
2025
Q3 | $10.4M | Buy |
22,862
+7,282
| +47% | +$2.97M | 0.01% | 542 |
|
|
2025
Q2 | $5.08M | Sell |
15,580
-519
| -3% | -$144K | ﹤0.01% | 750 |
|
|
2025
Q1 | $4.35M | Buy |
16,099
+5,286
| +49% | +$1.36M | ﹤0.01% | 763 |
|
|
2024
Q4 | $2.54M | Buy |
10,813
+801
| +8% | +$211K | ﹤0.01% | 989 |
|
|
2024
Q3 | $2.75M | Buy |
10,012
+1,978
| +25% | +$515K | ﹤0.01% | 905 |
|
|
2024
Q2 | $1.95M | Buy |
8,034
+3,110
| +63% | +$491K | ﹤0.01% | 997 |
|
|
2024
Q1 | $736K | Sell |
4,924
-148
| -3% | -$24.7K | ﹤0.01% | 1570 |
|
|
2023
Q4 | $971K | Buy |
5,072
+951
| +23% | +$162K | ﹤0.01% | 1244 |
|
|
2023
Q3 | $730K | Sell |
4,121
-835
| -17% | -$159K | ﹤0.01% | 1321 |
|
|
2023
Q2 | $941K | Buy |
4,956
+1,379
| +39% | +$273K | ﹤0.01% | 1157 |
|
|
2023
Q1 | $717K | Buy |
3,577
+314
| +10% | +$66K | ﹤0.01% | 1261 |
|
|
2022
Q4 | $775K | Buy |
3,263
+676
| +26% | +$144K | ﹤0.01% | 1163 |
|
|
2022
Q3 | $518K | Buy |
2,587
+62
| +2% | +$11.8K | ﹤0.01% | 1316 |
|
|
2022
Q2 | $368K | Buy |
2,525
+1,146
| +83% | +$163K | ﹤0.01% | 1475 |
|
|
2022
Q1 | $225K | Sell |
1,379
-337
| -20% | -$51.3K | ﹤0.01% | 1820 |
|
|
2021
Q4 | $291K | Buy |
1,716
+248
| +17% | +$46.1K | ﹤0.01% | 1639 |
|
|
2021
Q3 | $277K | Buy |
+1,468
| New | +$275K | ﹤0.01% | 1641 |
|
|
2019
Q3 | – | Sell |
-21,194
| Closed | -$1.54M | – | 1990 |
|
|
2019
Q2 | $1.54M | Buy |
+21,194
| New | +$1.63M | 0.01% | 582 |
|
|
2017
Q3 | – | Sell |
-1,045
| Closed | -$83K | – | 1943 |
|
|
2017
Q2 | $83K | Buy |
1,045
+38
| +4% | +$2.43K | ﹤0.01% | 2124 |
|
|
2017
Q1 | $52K | Buy |
1,007
+300
| +42% | +$13.9K | ﹤0.01% | 2441 |
|
|
2016
Q4 | $26K | Buy |
707
+95
| +16% | +$3.98K | ﹤0.01% | 2883 |
|
|
2016
Q3 | $41K | Buy |
612
+542
| +774% | +$38.2K | ﹤0.01% | 2514 |
|
|
2016
Q2 | $4K | Hold |
70
| – | – | ﹤0.01% | 3721 |
|
|
2016
Q1 | $4K | Sell |
70
-600
| -90% | -$39.9K | ﹤0.01% | 3666 |
|
|
2015
Q4 | $63K | Hold |
670
| – | – | ﹤0.01% | 1925 |
|
|
2015
Q3 | $54K | Buy |
+670
| New | +$74.4K | ﹤0.01% | 1982 |
|
|
2015
Q2 | – | Sell |
-70
| Closed | -$7K | – | 1162 |
|
|
2015
Q1 | $7K | Buy |
+70
| New | +$7.09K | ﹤0.01% | 3374 |
|
|
2014
Q4 | – | Sell |
-600
| Closed | -$47K | – | 4134 |
|
|
2014
Q3 | $47K | Buy |
+600
| New | +$38.7K | ﹤0.01% | 1960 |
|
Other funds holding ALNY
VPM
VCM
Creative Planning's ALNY Position: Q1 2026 in Review
Creative Planning increased its Alnylam Pharmaceuticals (ALNY) stake by 1.3% in Q1 2026, buying an estimated $104K and bringing the position to 24,122 shares worth $7.98M. The position accounts for 0.01% of the portfolio, ranked #843.
Creative Planning first reported a position in ALNY in Q3 2014 and has held it in 30 quarters since. The position peaked at $10.4M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Creative Planning held 24,122 shares of Alnylam Pharmaceuticals worth $7.98M as of Q1 2026.
- Creative Planning bought 307 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $104K.
- Alnylam Pharmaceuticals made up 0.01% of Creative Planning's portfolio in Q1 2026, its #843 holding.
- Creative Planning first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 30 quarters since.
- Creative Planning's Alnylam Pharmaceuticals position peaked at $10.4M in Q3 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.